Leading provider of healthcare products for women
) is scheduled to exhibit some of its newest offerings at the
annual meeting of the European Society of Radiology, during Mar
7-11, in Vienna, Austria. This offers an ideal platform for the
company to showcase its most recent products at the largest
radiological meeting in Europe - the European Congress of
Hologic will display its extensive suite of healthcare solutions
for the screening and diagnosis of breast cancer, breast biopsy,
osteoporosis risk assessment, medical MRI coils and extremity
imaging. Management is enthusiastic about its breast
tomosynthesis program including the introduction of a
tomosynthesis biopsy option for the company's Affirm breast
biopsy guidance system. Hologic will also conduct education
sessions and training workshops for tomosynthesis-guided breast
The company received the European CE Mark for its Selenia
Dimensions breast tomosynthesis system in 2008 following the U.S.
Food and Drug Administration approval in 2011. Apart from Selenia
system and the most recent innovation for the 3D technology
platform - a tomosynthesis biopsy option for the 'Affirm breast
biopsy guidance system', Hologic will also present its latest
version of C-View software. These offerings are expected to
improve standards of patient care and workflow efficiencies.
Moreover, Hologic is set to display two new products at ECR,
namely Selenia Dimensions Avia Package and Flouroscan InSight-FD
Mini C-arm. While the Avia Package provides cost effective 2D
screening and diagnostic solutions, the Mini C-arm will meet the
needs of orthopedic and extremity surgeons by improving workspace
access and ease of positioning.
Given that ECR hosts more than 20,000 participants representing
the medical specialty of radiology across Europe and the
Mediterranean, the exhibition presents a unique opportunity to
create brand awareness for Hologic and thereby promote its
The coherent focus on Selenia is encouraging following the
ongoing shift from Hologic's legacy Selenia product lines.
According to the company, its breast tomosynthesis technology is
'game-changing'. Notably, expectations from the technology are
sky-high. However, over the past few quarters, Hologic witnessed
several challenges in the form of economic uncertainties in
Europe, slower sales cycles and increasing pricing pressure.
In the light of these facts, the estimates for the ongoing fiscal
have remained stagnant over the last 90 days. Accordingly, the
stock carries a Zacks Rank #3 (Hold). While we remain on the
sidelines for Hologic, other medical stocks such as
), each carrying a Zacks Rank #1 (Strong Buy) are expected to do
CYBERONICS INC (CYBX): Free Stock Analysis
GIVEN IMAGING (GIVN): Free Stock Analysis
HOLOGIC INC (HOLX): Free Stock Analysis
MEDICAL ACTION (MDCI): Free Stock Analysis
To read this article on Zacks.com click here.